This week on NeurologyLive, there are a number of hot topics that we will be post ...
Intravenousocrelizumab (Ocrevus; Genentech) demonstrated noninferiority to oral fingolimod (Gilenya; Novartis) for ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable ...
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over ...
This episode, "Follow-Up Care and the Caregiver's Role in Managing Agitation," features the panel closing the series with a ...
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan. The FDA has ...
Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with ...
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results